The Usefulness of Postprandial Triglyceride for Assessment of Cardiovascular Risk

Seoul National University

Status: Completed

Conditions: Prediabetes; Diabetes

Treatments: Dietary Supplement: Oral fat tolerance test

Study type: Interventional

Funder types: Other

Identifiers

NCT01972542

SNUBH-ENDO4

Details and patient eligibility

About

The hypertriglyceridemia at fasting status has been known to be an important risk factor for cardiovascular disease (CVD). Recently, postprandial triglyceride (TG) levels draw an attention as a superior predictor of CVD because of non-fasting state for more than 12 hours and importance of triglyceride-rich lipoprotein.

We aim to investigate the relationship of postprandial triglyceride after fat tolerance test and intima-medial thickness and to suggest normal reference of postprandial triglyceride after fat tolerance test. In addition, we evaluate the correlation of postprandial triglyceride and incretin secretion after fat tolerance test Ultimately, we want to estimate clinical importance of postprandial triglyceride in assessment of cardiovascular risk.

Enrollment: 80 patients

Sex: All

Ages: 19 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• age : 19 ~ 70 yrs
• Type 2 diabetes : HbA1c <10%
• Prediabetic state : HbA1c 5.7~6.4%

Exclusion criteria

• Type 1 diabetes, secondary diabetes
• dipeptidyl peptidase-4 -inhibitor, glucagon-like peptide-1 agonist, thiazolidinediones users
• Thyroid disease with abnormal thyroid function test
• Liver disease with abnormal liver function test
• severe kidney disease
• pregnant or lactating women
• current smoker
• severe obesity

Trial design

Primary purpose: Screening

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

80 participants in 3 patient groups

Type 2 DM

Active Comparator group

Description:

Intervention : Oral fat tolerance test well or moderately controlled type 2 diabetes mellitus (HbA1c \< 10%) No dipeptidyl peptidase-4 -inhibitor, Glucagon-like peptide-1 agonist, thiazolidinediones

Treatment:

Dietary Supplement: Oral fat tolerance test

Prediabetes

Active Comparator group

Description:

Intervention : Oral fat tolerance test Glucose 140-199 mg/dL after 75g oral glucose tolerance test HbA1c 5.7-6.4%

Treatment:

Dietary Supplement: Oral fat tolerance test

Normal glucose tolerance

Sham Comparator group

Description:

Intervention : Oral fat tolerance test No impaired fasting glucose and impaired glucose tolerance

Treatment:

Dietary Supplement: Oral fat tolerance test